Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322734 · ClinicalTrials.gov registry record
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
A clinical trial of Autism Spectrum Disorder and Epilepsy, sponsored by Southwest Autism Research & Resource Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT04322734 is a study of Autism Spectrum Disorder and Epilepsy that is actively recruiting participants, run by Southwest Autism Research & Resource Center. The registered enrollment target is 500 participants, above the 133-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (276% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT04322734, a study of Autism Spectrum Disorder and Epilepsy, is actively recruiting participants, sponsored by Southwest Autism Research & Resource Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.
Conditions Studied
Study Locations (2)
Arizona
- Southwestern Research and Resource Center - Phoenix
New York
- State University of New York, Downstate - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2028-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322734
The ClinicalTrials.gov registry entry for NCT04322734 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (276% higher). The listed sponsor is Southwest Autism Research & Resource Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT04322734 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT04322734 about?
NCT04322734 is a clinical study titled "Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders". The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.
What is the current status of trial NCT04322734?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-12-13. Estimated completion is 2028-12-31.
What conditions does trial NCT04322734 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Epilepsy, Brain Tumor, Psychiatric Disorder, Mitochondrial Diseases.
Who is sponsoring clinical trial NCT04322734?
This trial is sponsored by Southwest Autism Research & Resource Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322734 being conducted?
This trial has 2 study locations across Arizona, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.